143 related articles for article (PubMed ID: 2977221)
41. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
42. A dual anti-tumor effect of a combination of interferon-alpha and 5-flurouracil or 2-chlorodeoxyadenosine on natural killer (NK) cell mediated cytotoxicity.
Reiter Z; Ozes ON; Tomson S; Blatt LM; Taylor MW
Adv Exp Med Biol; 1991; 309A():69-73. PubMed ID: 1686352
[No Abstract] [Full Text] [Related]
43. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Bonavida B; Nio Y; Yoshida O
Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
[TBL] [Abstract][Full Text] [Related]
44. [Natural killer cells lysing the blood B-lymphocytes of patients with chronic lympholeukemia].
Khonina NA; Shubinskiĭ GZ
Eksp Onkol; 1988; 10(4):44-6. PubMed ID: 3263265
[TBL] [Abstract][Full Text] [Related]
45. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
46. [Mechanism of action of interferon-alpha 2 in hairy cells and lymphoblastoid cell lines: the significance of type I interferon receptors and RNA synthesis].
Schwabe M; Wagner L; Prischl F; Pinter G; Schwarzmeier JD
Onkologie; 1988 Aug; 11(4):155-8. PubMed ID: 2972979
[TBL] [Abstract][Full Text] [Related]
47. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia.
Foa R; Fierro MT; Lusso P; Bonferroni M; Raspadori D; Buzzi M; Zinzani PL; Resegotti L; Lauria F
Leukemia; 1987 Apr; 1(4):377-9. PubMed ID: 3499543
[TBL] [Abstract][Full Text] [Related]
48. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
[TBL] [Abstract][Full Text] [Related]
49. The use of VEP13 monoclonal antibody for definition of natural killer cells: spontaneous killer cells directed against fresh human leukaemia cells carry the VEP13 antigen.
Ziegler-Heitbrock HW; Fütterer A; Rumpold H; Kraft D; Munker R; Riethmüller G
Clin Exp Immunol; 1984 Nov; 58(2):470-7. PubMed ID: 6333947
[TBL] [Abstract][Full Text] [Related]
50. Natural anti-chondrocyte cytotoxicity of normal human peripheral blood mononuclear cells.
Malejczyk J
Clin Immunol Immunopathol; 1989 Jan; 50(1 Pt 1):42-52. PubMed ID: 2783400
[TBL] [Abstract][Full Text] [Related]
51. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
Teichmann JV; Ludwig WD; Thiel E
Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
[TBL] [Abstract][Full Text] [Related]
52. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
53. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.
Manning LS; Bowman RV; Darby SB; Robinson BW
Am Rev Respir Dis; 1989 Jun; 139(6):1369-74. PubMed ID: 2786360
[TBL] [Abstract][Full Text] [Related]
54. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
de Fries RU; Golub SH
J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
[TBL] [Abstract][Full Text] [Related]
55. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity.
Chilosi M; Semenzato G; Cetto G; Ambrosetti A; Fiore-Donati L; Perona G; Berton G; Lestani M; Scarpa A; Agostini C
Blood; 1987 Nov; 70(5):1530-5. PubMed ID: 3117133
[TBL] [Abstract][Full Text] [Related]
56. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
57. Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway.
Kaser A; Enrich B; Ludwiczek O; Vogel W; Tilg H
Clin Exp Immunol; 1999 Oct; 118(1):71-7. PubMed ID: 10540162
[TBL] [Abstract][Full Text] [Related]
58. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia.
Panayiotidis P; Ganeshaguru K; Foroni L; Hoffbrand AV
Leukemia; 1995 Jul; 9(7):1227-32. PubMed ID: 7543175
[TBL] [Abstract][Full Text] [Related]
59. Human recombinant interferon alpha-2C enhances the expression of class II HLA antigens on hairy cells.
Baldini L; Cortelezzi A; Polli N; Neri A; Nobili L; Maiolo AT; Lambertenghi-Deliliers G; Polli EE
Blood; 1986 Feb; 67(2):458-64. PubMed ID: 2935210
[TBL] [Abstract][Full Text] [Related]
60. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
